SHOCKIS / CLINICAL APPLICATION
Plantar Fasciopathy
Plantar fasciopathy — commonly referred to as plantar fasciitis — presents as pain at the insertion of the plantar fascia on the calcaneus (calcaneal insertional tendinopathy).
Disease Overview
Plantar fasciopathy — commonly referred to as plantar fasciitis — presents as pain at the insertion of the plantar fascia on the calcaneus (calcaneal insertional tendinopathy). Evidence indicates that this condition is not primarily an inflammatory process, but rather is associated with degenerative changes in the fascia caused by repeated microtrauma that exceeds the body's healing capacity. It is the most common cause of plantar heel pain, accounting for a substantial proportion of foot complaints that require professional treatment.
Typical Symptoms and Associated Factors
The classic symptom is pain at the bottom of the heel during weight-bearing, particularly during the first few steps after waking up in the morning. The pain is often described as sharp or stabbing, and can usually be reproduced by applying firm thumb pressure over the medial calcaneal tubercle. The pain may ease after initial activity, but can worsen again after prolonged weight-bearing. The characteristic post-rest pain pattern — worsening after rest or sleep — is a clinical hallmark of this condition.
Recognized associated factors include shortening or contracture of the Achilles tendon and plantar fascia, prolonged standing or walking on hard surfaces, high-arched or low-arched feet, and elevated body mass index. The condition is most common in middle-aged overweight or obese adults, and also occurs in athletes and runners. Associated comorbidities may include obesity, rheumatoid arthritis, and spondyloarthropathies.

Professional Evaluation
The diagnosis is primarily based on medical history and physical examination. No laboratory tests can confirm or rule out this diagnosis. In typical cases, plain radiography offers limited benefit; most current authors consider plantar calcaneal spurs an incidental finding rather than a cause of symptoms. When the diagnosis is uncertain or other causes need to be excluded, imaging studies such as ultrasound or MRI may be considered. Differential diagnoses should include calcaneal stress fracture, nerve entrapment, and inflammatory arthropathy.

Conservative Management
Non-surgical treatment is the standard of care for acute heel pain, although a subset of cases remains refractory after 12 months of non-surgical management. Conservative treatment options are selected based on the patient's symptoms and clinical assessment. Available measures may include activity modification, stretching exercises targeting the plantar fascia and calf muscles, footwear optimization, orthotic support, heel cups, Low-Dye taping, and non-steroidal anti-inflammatory drugs, depending on the individual clinical situation.

Extracorporeal Shock Wave Therapy: Potential Mechanisms and Limitations of Evidence
A 2025 network meta-analysis shows that ESWT at all intensity levels outperforms placebo in overall success rate, but only medium and high intensities yield statistically significant advantages in pain relief. The certainty of evidence is rated as low to very low, and a considerable number of trials carry a high risk of bias. The 2003 multicenter double-blind RCT by Haake et al. demonstrates that among patients with chronic plantar fasciitis refractory to ≥6 months of conservative treatment, there is no statistically significant difference in success rates between the ESWT group and the placebo group at the 12-week follow-up. The authors concluded that ESWT was ineffective under this study population and treatment protocol. The discrepancies in results may be related to treatment protocols, energy levels, shock wave types, patient selection, outcome measures, and whether the therapy is combined with rehabilitation. NICE holds that ESWT does not raise major safety concerns, but the efficacy evidence is inconsistent. It recommends that the procedure be used only under special arrangements such as clinical governance, informed consent, audit or research.

Safety Profile
Within the scope of evidence reviewed in the above studies and assessments, ESWT for plantar fasciopathy is generally associated with transient and mild adverse reactions. A systematic review of complications by Roerdink et al. reported 2 complications (precordial pain and superficial skin infection after regional anesthesia) across 39 studies, while commonly reported mild reactions included transient post-treatment pain, swelling, bruising, and/or petechiae. This review considered ESWT to be a safe treatment option for plantar fasciopathy, but long-term complications remain unknown based on the current literature. NICE similarly found no major safety concerns in its assessment.
These findings should be interpreted in the context of the limitations of the reviewed studies. Appropriate patient screening for contraindications, adherence to device-specific instructions for use, and sound professional clinical judgment remain essential. The favorable safety profile reported in these studies does not imply that ESWT is risk-free or suitable for all patients.
Contact with SHOCKIS
Clinicians and procurement professionals evaluating shock wave therapy systems for plantar fasciopathy should consider device-specific characteristics and the applicable regulatory status in their respective regions. The evidence presented above reflects the broader ESWT literature and does not constitute validation of any specific SHOCKIS product for any particular indication. If you wish to discuss how SHOCKIS can support your clinical or procurement needs, our team is welcome to hear from you.
Clinical Workflow Checklist
- 01CLINICAL ASSESSMENT
Review patient history, symptoms, and contraindications.
- 02TARGET AREA IDENTIFICATION
Identify the treatment area through clinical examination and appropriate imaging when needed.
- 03TREATMENT SETUP
Select treatment parameters according to clinical assessment, device instructions, and patient tolerance.
- 04SHOCKWAVE APPLICATION
Apply coupling gel and deliver treatment while monitoring patient response.
- 05POST-TREATMENT CARE
Clean the treatment area and applicator, and provide appropriate aftercare guidance.
Safety Information
The information below describes conditions and reactions generally associated with extracorporeal shock wave therapy. It does not replace the instructions for use of the specific SHOCKIS device. Clinicians must verify applicability against the current device labeling and their own clinical judgment.
Contraindications & Precautions
Shock wave therapy should not be applied, or should be applied only with particular caution, in the following situations:
- Known hemorrhagic disorders or coagulation dysfunction
- Thrombosis in or adjacent to the intended treatment area
- Severe cognitive impairment or psychiatric illness
- Implanted pacemakers or other active electronic implants
- Tumors located in the treatment area
- Pregnancy, particularly the lower abdominal region
- Ruptured or severely injured tendons and fasciae, as well as regions containing the brain, spinal cord, large blood vessels, or major nerve trunks
- Regions containing abdominal organs, especially lung tissue
- Bone defects exceeding 2 cm
- Joint fluid leakage
- Growing pains in pediatric patients
Any other condition deemed unsuitable by the treating physician.
Potential Adverse Reactions
The following reactions may occur at or near the treatment site:
- Local hematoma, ecchymosis, or petechiae
- Temporary intensification of pain shortly after treatment
- Local numbness, needle-like sensation, or hypoesthesia
- High-energy extracorporeal shock wave therapy may cause local nerve or vascular injury
These reactions are generally transient and typically resolve within approximately one week without special treatment.
References
- [1] Haake M, Buch M, Schoellner C, et al. Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. BMJ. 2003;327(7406):75. DOI: 10.1136/bmj.327.7406.75. PMID: 12855524.
- [2] Zhao P, He Y, Li M, et al. Comparative efficacy and acceptability of different intensity levels of extracorporeal shock wave therapy in adults with plantar heel pain: A systematic review and network meta-analysis. PM R. 2025;17(12):1481-1493. DOI: 10.1002/pmrj.13417. PMID: 40709373.
- [3] Roerdink RL, Dietvorst M, van der Zwaard B, van der Worp H, Zwerver J. Complications of extracorporeal shockwave therapy in plantar fasciitis: Systematic review. Int J Surg. 2017;46:133-145. DOI: 10.1016/j.ijsu.2017.08.587. PMID: 28890412.
- [4] National Institute for Health and Care Excellence. Extracorporeal shockwave therapy for refractory plantar fasciitis. HealthTech guidance 200. 2009 (migrated from IPG311).